Using video therapy and financial incentives to improve treatment for latent tuberculosis
Economic Incentives and Video Directly Observed Therapy to Promote Adherence to Latent Tuberculosis Infection
NA · Johns Hopkins University · NCT05022862
This study is testing whether combining video therapy with financial rewards can help adults with latent tuberculosis stick to their treatment better than standard care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 399 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Johns Hopkins University (other) |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT05022862 on ClinicalTrials.gov |
What this trial studies
This study evaluates a new approach that combines Video Directly Observed Therapy (vDOT) with financial incentives to enhance treatment completion rates for latent tuberculosis (LTBI). Adult participants diagnosed with LTBI will be recruited from the Baltimore City Health Department. The study aims to compare the effectiveness of vDOT alone and vDOT with financial incentives against usual care in promoting adherence to LTBI treatment. The intervention addresses barriers such as socioeconomic factors and competing health priorities that often hinder treatment completion.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with latent tuberculosis who reside in the Baltimore metro area and can communicate in English or Spanish.
Not a fit: Patients with active tuberculosis, those under 18 years old, or individuals prescribed alternative treatment regimens for latent TB may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase the number of patients completing treatment for latent tuberculosis, thereby contributing to TB elimination efforts.
How similar studies have performed: Previous studies have shown that financial incentives can effectively promote adherence to treatment in various populations, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old or older, * diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians * reside in Baltimore metro area * speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board * prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin Exclusion Criteria: * younger than 18 years old * diagnosed with active TB * prescribed an alternative treatment regimen for latent TB * pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated) * participant's spoken language does not have a translated long or short consent form
Where this trial is running
Baltimore, Maryland
- Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments — Baltimore, Maryland, United States (RECRUITING)
Study contacts
- Principal investigator: Maunank Shah, MD, PhD — Johns Hopkins University
- Study coordinator: Principal Investigator
- Email: mshah28@jhmi.edu
- Phone: 443-287-0401
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Latent Tuberculosis, Video Directly Observed Therapy